INPROTHER ApS

InProther ApS, operating under its secondary name HERVolution Therapeutics ApS, is a preclinical biotechnology company developing immunotherapies that harness the untapped potential of the Dark Genome. The Company's​proprietary engineering platform redesigns Human Endogenous Retroviruses (HERVs) to disrupt immune tolerance, enabling the immune system to detect and act on these antigens for the first time. This approach gives​rise to ready-to-use immunotherapies addressing serious unmet medical needs in oncology and in age-related metabolic and neurodegenerative diseases. ​​The Company's lead candidate, IPT-001, is a dual adenoviral (Ad) vector immunotherapy. It uses two proprietary Ad-vectors that show low pre-existing immunity and strong antigen expression, enabling the concurrent activation of potent HERV-specific T and B cell responses. IPT-001 is being advanced toward first-in-human clinical​evaluation. In parallel, HERVolution is progressing IPT-002, an mRNA vector expressing the proprietary HERV antigen, which is intended to facilitate repeated dosing in patients and to enhance anti-HERV immune responses through a prime-boost treatment approach in combination with IPT-001.